Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis

Menopause

Volumn 16, Issue 5, 2009, Pages 978-983

  Chollet, Janet A ^a   Carter, Gloria ^b   Meyn, Leslie A ^b   Mermelstein, Fred ^c   Balk, Judith L ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c Peartree Women's Healthcare   (United States)

Author keywords

Atrophic vaginitis; Intravaginal estriol and progesterone; Postmenopausal women

Indexed keywords

ESTRIOL; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; POSTMENOPAUSE; QUALITY OF LIFE; VAGINA; VAGINA ATROPHY; VAGINA PH; VAGINAL DRYNESS; VAGINAL MATURATION INDEX;

ADMINISTRATION, INTRAVAGINAL; AGED; ATROPHY; DRUG THERAPY, COMBINATION; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; POSTMENOPAUSE; PROGESTERONE; QUALITY OF LIFE; QUESTIONNAIRES; SAFETY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VAGINA; VAGINITIS;

EID: 73349092733     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a06c80     Document Type: Article

References (19)

1. Mishell DR Jr, Stenchever MA, Droegemueller W, Herbst AL. Comprehensive Gynecology, 3rd ed. Philadelphia, PA: Mosby, 1997:1113-1159.
2. Dennerstein L, Dudly EC, Hooper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-358. (Pubitemid 30674275)
3. FDA. Guidance for Industry: Labeling guidance for noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar atrophy symptoms-prescribing information for health care providers and patient labeling. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed January 2003.
4. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2006;8:83-92. (Pubitemid 40675125)
5. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84:215-218.
6. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen, cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 2001;27:255-260. (Pubitemid 33121175)
7. Rioux JE, Devlin CE, Gelfand MM, Steinberg WM, Hepburn. DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7: 140-142.
8. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal, women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:357-369.
9. Notelovitz M. Editorial: urogenital atrophy and low-dose vaginal estrogen, therapy. Menopause 2000;7:140-142. (Pubitemid 30249893)
10. Ficicioglu C, Gurbuz S, Tasdemir S, Yaití S, Canova H. High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol 2004;18:240-243. (Pubitemid 38746358)
11. Hilditch JR, Lewis J, Peter A, et al. The menopausal-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175. (Pubitemid 26241870)
12. Marx P, Schade G, Wilbourn S, et al. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas 2004;47:47-54. (Pubitemid 38050015)
13. Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004; 11:49-56. (Pubitemid 40362198)
14. Kicovic PM, Cortes-Prieto J, Milojević S, Haspels AA, Aljinovic A. The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream. or suppositories: clinical, endocrinological and safety aspects. Maturitas 1980;2:275-282. (Pubitemid 11170804)
15. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107.
16. Tong YC, Hung YC, Lin JSN, Hsu CT, Cheng JT. Effects of pregnancy and progesterone on autonomic function in rat urinary bladder. Pharmacology 1995;50:192-200.
17. Rodriguez LV, Wang B, Shortliffe LM. Structural changes in the bladder walls of pregnant and hormone-treated rats: correlation with bladder dynamics. BJU Int 2004;94:1366-1372. (Pubitemid 40052110)
18. MacLennan AH, Sturdee DW. Is endometrial, monitoring required with the use of long-term unopposed vaginal estrogen? Climacteric 2006;9:321-322.
19. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? JAMA 1983;249:1743-1745.